Biomarkers predict kidney cancer treatment outcomes

Two recent studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago this week, suggest that levels of a protein called hepatocyte growth factor (HGF) in the blood, and certain changes (mutations) in the genes called┬áBAP1 and PBRM1 in kidney cancer tumours are promising biomarkers for the prediction of survival […]

read more

Potential novel biomarker for kidney cancer

A novel potential biomarker for renal cell carcinoma (RCC) tumours has been discovered. Levels of a protein called progesterone receptor membrane component 1 (PGRMC1) have been shown to be raised in a number of different human cancers; however, the roles of PGRMC1 in renal cancer are not clear and merit further study. In the current […]

read more

Side effects to mTOR drugs could be used as biological markers of efficacy in kidney cancer

A recent study published online in BioMed Central Cancer shows how the presence and onset rate of side effects to treatment with mTOR inhibitors, such as everolimus, is associated with tumour response and progression free survival. From 2007 to 2011, metabolic toxicities were collected retrospectively from patients treated with an mTOR inhibitor (everolimus, temsirolimus) for […]

read more
Showing 51 to 53 of 53 results